FOXX
Foxx Development Holdings Inc.
Consumer Electronics
Market Cap$33M
5Y Perf.-51.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FOXX vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-54.9%
FOXX vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FOXX | XTLB |
|---|---|---|
| Industry | Consumer Electronics | Biotechnology |
| Market Cap | $33M | $294K |
| Revenue (TTM) | $63M | $451K |
| Net Income (TTM) | $-10M | $-1M |
| Gross Margin | 11.3% | 26.4% |
| Operating Margin | -13.9% | -481.6% |
| Total Debt | $1M | $138K |
| Cash & Equiv. | $2M | $371K |
FOXX vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FOXX
XTLB
| Stock | Aug 22 | May 26 | Return |
|---|---|---|---|
| Foxx Development Ho… (FOXX) | 100 | 48.1 | -51.9% |
| XTL Biopharmaceutic… (XTLB) | 100 | 45.1 | -54.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FOXX vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FOXX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. XTL Biopharmaceuticals Ltd. is the stronger pick specifically for operational efficiency and capital deployment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
FOXX
Foxx Development Holdings Inc.
The Income Pick
FOXX carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.36
- -52.1% 10Y total return vs XTLB's -87.3%
- Lower volatility, beta 1.36, current ratio 0.78x
Best for: income & stability and long-term compounding
XTLB
XTL Biopharmaceuticals Ltd.
The Growth Play
XTLB is the clearest fit if your priority is growth exposure.
- EPS growth 45.5%
- -17.7% ROA vs FOXX's -19.3%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FOXX | 19.4% revenue growth vs XTLB's -173.2% |
| Quality / Margins | FOXX | -15.3% margin vs XTLB's -227.7% |
| Stability / Safety | FOXX | Beta 1.36 vs XTLB's 1.71 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FOXX | -15.8% vs XTLB's -50.9% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs FOXX's -19.3% |
FOXX vs XTLB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FOXX vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFOXXLAGGINGXTLB
XTLBXTL Biopharmaceutical…
0leads
FOXXFoxx Development Hold…
5leads
6 Total Categories
CATEGORYLEADERvs XTLBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FOXX4/5
Valuation MetricsMultiples, price ratios, and targets
FOXX2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FOXX3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
FOXX4/6
Risk & VolatilityBeta, volatility, and downside exposure
FOXX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FOXX leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
FOXX is the larger business by revenue, generating $63M annually — 139.8x XTLB's $451,000. Profitability is closely matched — net margins range from -15.3% (FOXX) to -2.3% (XTLB).
| Metric | FOXXFoxx Development … | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $63M | $451,000 |
| EBITDAEarnings before interest/tax | -$8M | -$1M |
| Net IncomeAfter-tax profit | -$10M | -$1M |
| Free Cash FlowCash after capex | -$7M | $0 |
| Gross MarginGross profit ÷ Revenue | +11.3% | +26.4% |
| Operating MarginEBIT ÷ Revenue | -13.9% | -4.8% |
| Net MarginNet income ÷ Revenue | -15.3% | -2.3% |
| FCF MarginFCF ÷ Revenue | -10.7% | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -12.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +35.4% | +20.0% |
FOXX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
FOXX leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | FOXXFoxx Development … | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $33M | $293,767 |
| Enterprise ValueMkt cap + debt − cash | $32M | $60,767 |
| Trailing P/EPrice ÷ TTM EPS | -3.27x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.49x | 0.65x |
| Price / BookPrice ÷ Book value/share | — | 0.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
FOXX leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
FOXX leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), FOXX scores 7/9 vs XTLB's 3/9, reflecting strong financial health.
| Metric | FOXXFoxx Development … | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | — | -25.5% |
| ROA (TTM)Return on assets | -19.3% | -17.7% |
| ROICReturn on invested capital | — | -54.1% |
| ROCEReturn on capital employed | — | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | -$676,940 | -$233,000 |
| Cash & Equiv.Liquid assets | $2M | $371,000 |
| Total DebtShort + long-term debt | $1M | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -0.45x | -13.31x |
FOXX leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
FOXX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOXX five years ago would be worth $4,786 today (with dividends reinvested), compared to $1,963 for XTLB. Over the past 12 months, FOXX leads with a -15.8% total return vs XTLB's -50.9%. The 3-year compound annual growth rate (CAGR) favors XTLB at -18.4% vs FOXX's -23.2% — a key indicator of consistent wealth creation.
| Metric | FOXXFoxx Development … | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +13.5% | +11.3% |
| 1-Year ReturnPast 12 months | -15.8% | -50.9% |
| 3-Year ReturnCumulative with dividends | -54.6% | -45.7% |
| 5-Year ReturnCumulative with dividends | -52.1% | -80.4% |
| 10-Year ReturnCumulative with dividends | -52.1% | -87.3% |
| CAGR (3Y)Annualised 3-year return | -23.2% | -18.4% |
FOXX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
FOXX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOXX is the less volatile stock with a 1.36 beta — it tends to amplify market swings less than XTLB's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOXX currently trades 54.1% from its 52-week high vs XTLB's 26.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FOXXFoxx Development … | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 1.71x |
| 52-Week HighHighest price in past year | $8.88 | $10.28 |
| 52-Week LowLowest price in past year | $1.71 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +54.1% | +26.0% |
| RSI (14)Momentum oscillator 0–100 | 39.9 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 11K | 2.4M |
FOXX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | FOXXFoxx Development … | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FOXX leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
Best OverallFoxx Development Holdings I… (FOXX)Leads 5 of 6 categories
Loading custom metrics...
FOXX vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — FOXX or XTLB?
Over the past 5 years, Foxx Development Holdings Inc.
(FOXX) delivered a total return of -52. 1%, compared to -80. 4% for XTL Biopharmaceuticals Ltd. (XTLB). Over 10 years, the gap is even starker: FOXX returned -52. 1% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — FOXX or XTLB?
By beta (market sensitivity over 5 years), Foxx Development Holdings Inc.
(FOXX) is the lower-risk stock at 1. 36β versus XTL Biopharmaceuticals Ltd. 's 1. 71β — meaning XTLB is approximately 26% more volatile than FOXX relative to the S&P 500.
03Which has better profit margins — FOXX or XTLB?
Foxx Development Holdings Inc.
(FOXX) is the more profitable company, earning -13. 7% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps -13. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOXX leads at -14. 7% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — FOXX leads at 7. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — FOXX or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is FOXX or XTLB better for a retirement portfolio?
For long-horizon retirement investors, Foxx Development Holdings Inc.
(FOXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. XTL Biopharmaceuticals Ltd. (XTLB) carries a higher beta of 1. 71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FOXX: -52. 1%, XTLB: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between FOXX and XTLB?
These companies operate in different sectors (FOXX (Technology) and XTLB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FOXX is a small-cap high-growth stock; XTLB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.